HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Chronic hepatitis B (CHB) affects more than 350 million people worldwide. The most common
form in Europe is CHB HBeAg-negative. Antiviral treatment of CHB HBeAg-negative patients
includes chronic administration of nucleos(t)ide analogues (NUC) or pegylated interferon
(PegIFN) during 12 months. Typically, PegIFN allows immune control of CHB and antigen "s"
(HBsAg) loss in around 4% of patients compared to less than 0,1% using NUC. Recently, it has
been described that HBsAg quantification (HBsAg-q) is useful to identify patients with high
probability to lose HBsAg during follow-up. In addition, a proof-of-concept study with nine
HBeAg-negative patients receiving NUC showed that adding PegIFN (16 weeks) achieved HBsAg
loss in one patient (11%). The aim of our study is to evaluate the efficacy and safety adding
PegIFN (48 weeks) in treated HBeAg-negative patients with NUC.